CLEVELAND, Oct. 2, 2018 /PRNewswire/
-- ViewRay, Inc. (Nasdaq: VRAY), maker of the MRIdian, which
combines MRI and external-beam radiation therapy to simultaneously
image and treat cancer patients, today announced the
appointment of James "Jim" Alecxih as Chief Commercial Officer,
effective September 17th,
2018. Mr. Alecxih joins the ViewRay leadership team with extensive
experience in commercializing new and innovative devices globally
and will be responsible for driving the Company's commercial
expansion.
Prior to joining ViewRay, Mr. Alecxih served as Vice President
of Worldwide Sales at Nevro, where he led the high-growth
neuromodulation device company's commercial efforts across multiple
geographies. Mr. Alecxih also spent 14 years at Intuitive
Surgical, where he served most recently as Senior Vice President of
Sales for North America,
South America, Australia and New
Zealand. At Intuitive Surgical, Jim was integral in driving
sales from $9 million annually to
more than $1.8 billion annually and
coordinated the overall marketing strategy through four product
launches and domestic and international expansion.
Earlier in his career, Mr. Alecxih held a variety of sales
management roles at Johnson & Johnson's Ethicon Endo-Surgery.
He holds a Bachelor of Arts degree in Business from Le Tourneau
University.
"We are excited to welcome Jim as our Chief Commercial Officer
as we drive the commercial adoption of the MRIdian system,"
said Scott Drake, President and Chief Executive Officer of
ViewRay. "We are committed to extending our leadership
position in the market. Jim's proven track record and relevant
experience complement our strategic plans and help drive our
ambitious growth goals."
As an inducement material to Mr. Alecxih's entering into
employment with ViewRay, ViewRay has agreed to grant Mr. Alecxih a
total of 275,000 stock options, effective October 15, 2018. This award will be granted in
accordance with Nasdaq Listing Rule 5635(c)(4), has been approved
by the Compensation Committee of ViewRay's Board of Directors and
will be subject to the terms and conditions of ViewRay's 2015 Stock
Incentive Plan and Mr. Alecxih's award agreement. These terms will
include a service-based vesting requirement, with the stock options
vesting over four years. The options will have an exercise price
equal to the closing trading price of ViewRay's common stock on the
effective date.
About ViewRay
ViewRay®, Inc. (Nasdaq:
VRAY), designs, manufactures and markets the MRIdian® radiation
therapy system. MRIdian is built upon a proprietary
high-definition MR imaging system designed from the ground up to
address the unique challenges and clinical workflow for advanced
radiation oncology helping to transform radiation therapy,
resulting in improved treatment outcomes that benefit both patients
and health care systems around the world. Unlike MR systems used in
diagnostic radiology, MRIdian's high-definition MR was purposely
built to deliver high-precision radiation without unnecessary beam
distortion, and consequently, help to mitigate skin toxicity and
other safety concerns that may otherwise arise when high magnetic
fields interact with radiation beams. ViewRay and MRIdian are
registered trademarks of ViewRay, Inc.
Forward Looking Statements:
This press release
contains forward-looking statements. Statements in this press
release that are not purely historical are forward-looking
statements. These forward-looking statements are made as of the
date of this press release, and ViewRay assumes no obligation to
update the forward-looking statements, or to update the reasons why
actual results could differ from those projected in the
forward-looking statements, except as required by law. Investors
should consult all of the information set forth herein and should
also refer to the risk factor disclosure set forth in the reports
and other documents ViewRay files with the SEC available at
www.sec.gov, including the risk factors disclosed in ViewRay's
Quarterly Report on Form 10-Q for the quarter ended June 30, 2018.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/viewray-appoints-industry-veteran-james-alecxih-as-chief-commercial-officer-300722519.html
SOURCE ViewRay, Inc.